[go: up one dir, main page]

MX2014001767A - Metodos para reducir sintomas o condiciones causados por estres. - Google Patents

Metodos para reducir sintomas o condiciones causados por estres.

Info

Publication number
MX2014001767A
MX2014001767A MX2014001767A MX2014001767A MX2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A MX 2014001767 A MX2014001767 A MX 2014001767A
Authority
MX
Mexico
Prior art keywords
stress
conditions caused
methods
ameliorating symptoms
fatty acid
Prior art date
Application number
MX2014001767A
Other languages
English (en)
Inventor
Yuanlong Pan
Delphine Tissot-Favre
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2014001767A publication Critical patent/MX2014001767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)

Abstract

La invención proporciona métodos para usar alcanolamidas de ácido graso para mejorar uno o más síntomas o condiciones causados por estrés, por ejemplo, pérdida de apetito, o para mantener y mejorar la ingesta de nutrientes y calorías en un animal bajo estrés o que haya experimentado estrés. Generalmente, las alcanolamidas de ácido graso se administran en cantidades de 0.1 a 1500 mg/kg/día antes, durante o después del estrés, preferentemente sobre una base regular o diaria como un componente de una composición alimenticia o como un suplemento dietético.
MX2014001767A 2011-08-15 2012-08-07 Metodos para reducir sintomas o condiciones causados por estres. MX2014001767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161575073P 2011-08-15 2011-08-15
PCT/US2012/049825 WO2013025399A1 (en) 2011-08-15 2012-08-07 Methods for ameliorating symptoms or conditions caused by stress

Publications (1)

Publication Number Publication Date
MX2014001767A true MX2014001767A (es) 2014-05-01

Family

ID=47715371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001767A MX2014001767A (es) 2011-08-15 2012-08-07 Metodos para reducir sintomas o condiciones causados por estres.

Country Status (10)

Country Link
US (1) US20140199267A1 (es)
EP (1) EP2744488A4 (es)
JP (1) JP2014525931A (es)
CN (1) CN103917230A (es)
AU (1) AU2012295432A1 (es)
BR (1) BR112014003445A2 (es)
CA (1) CA2846213A1 (es)
MX (1) MX2014001767A (es)
RU (1) RU2014110056A (es)
WO (1) WO2013025399A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178151A1 (en) 2008-03-04 2011-07-21 Yissum Research Development Company Of The Hebrew Compounds and methods of treating obesity
US20150202179A1 (en) * 2012-07-20 2015-07-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fatty acid derivatives for use in a method of treating depression and associated conditions
JP6563218B2 (ja) * 2015-03-13 2019-08-21 ユニ・チャーム株式会社 ペットフードの製造方法
KR101997028B1 (ko) * 2018-11-30 2019-07-05 강원대학교산학협력단 각성 강화용 유산균 혼합 조성물 및 이의 용도
US20230000933A1 (en) * 2019-12-02 2023-01-05 Life Quality Institute, Inc. Agent for prevention or remediation of stress disorders and composition containing same
CN117143760B (zh) * 2023-07-12 2024-09-20 西南大学 一株能促进5-htp分泌及缓解抑郁的鼠李糖乳酪杆菌ky16及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
US20070155747A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CN101351495A (zh) * 2005-12-29 2009-01-21 欧加农股份有限公司 脂肪酸酰胺水解酶抑制剂
US20080089845A1 (en) * 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
BRPI0912774A2 (pt) * 2008-05-19 2017-05-23 Nestec Sa métodos para reduzir absorção de lipídio por um animal
US20100190860A1 (en) * 2009-01-09 2010-07-29 The Brigham And Women's Hospital, Inc. Methods for selectively enhancing antinociceptive potency of local anesthetics

Also Published As

Publication number Publication date
US20140199267A1 (en) 2014-07-17
RU2014110056A (ru) 2015-09-27
JP2014525931A (ja) 2014-10-02
CN103917230A (zh) 2014-07-09
BR112014003445A2 (pt) 2018-03-20
WO2013025399A1 (en) 2013-02-21
EP2744488A4 (en) 2014-07-09
CA2846213A1 (en) 2013-02-21
EP2744488A1 (en) 2014-06-25
AU2012295432A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
MX2014001767A (es) Metodos para reducir sintomas o condiciones causados por estres.
WO2013049519A3 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
WO2013153071A3 (en) A nutritional composition
MY165142A (en) Metabolic imprinting effects of specifically designed lipid component
PH12012502318A1 (en) Substantially clear nutritional liquids comprising calcium hmb and soluble protein
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
EA201070419A1 (ru) Состав для регулирования метаболизма липидов
PH12012501823A1 (en) Infant nutrition for improving fatty acid composition of brain membranes
MX338245B (es) Metodos y composicioes para inducir la saciedad.
MX2010004642A (es) Procedimiento para reducir el contenido en acidos grasos saturados de la grasa de leche, productos obtenidos y aplicaciones del mismo.
MY166855A (en) Device For Processing Plant Remnants
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
WO2011092473A8 (en) Novel compounds and their effects on feeding behaviour
WO2013028555A3 (en) Methods for weight loss and ketogenic compositions
PH12013502158A1 (en) Fortified milk-based nutritional compositions
MY172574A (en) Dicaffeoylquinic acid-containing drink
WO2010119424A3 (fr) Composition destinee a la regulation du metabolisme des lipides
ECSP13012798A (es) Método para inhibir patógenos usando una composición nutricional
PH12013500917A1 (en) Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions
MY169098A (en) Ready to drink beverages and methods of making thereof
BR112012016054A2 (pt) Composições nutricionais compreendendo flocos de fruta incluindo ácido docosa-hexaenoico
MX2011007222A (es) Composicion nutricional para infantes.
PT2477503E (pt) Processo de preparação de um produto lácteo pasteurizado e fermentado, suplementado com cálcio e vitamina d
WO2010072209A3 (de) Nahrungsergänzungsmittel auf der basis von pantothensäure
BR112014003545A2 (pt) método para transformar uma refeição